Relay Therapeutics, Inc. (RLAY) Discusses Mutant Selective PI3K-alpha Inhibitor for PIK3CA-Driven Vascular Anomalies - Slideshow (NASDAQ:RLAY)
Relay Therapeutics, Inc. (RLAY) held an event to discuss its mutant selective PI3K-alpha inhibitor, focusing on its potential application for PIK3CA-driven vascular anomalies. The company released a slide deck in conjunction with this discussion. The article highlights this presentation, indicating the company's efforts in developing treatments for specific genetic conditions.
Is Relay Therapeutics (RLAY) Building a Durable Precision-Medicine Platform with Its Zovegalisib Strategy?
Relay Therapeutics is leveraging its PI3Kα inhibitor, zovegalisib, for both PIK3CA-driven vascular anomalies and certain breast cancers, aiming to establish a durable precision-medicine platform. Upcoming clinical data for zovegalisib in vascular anomalies will be presented at a May congress, serving as a near-term catalyst. Despite its potential, Relay remains a clinical-stage company facing significant annual losses, an unclear path to profitability, and recent insider selling, making trial outcomes and regulatory feedback critical.
SG Americas Securities LLC Acquires 189,004 Shares of Relay Therapeutics, Inc. $RLAY
SG Americas Securities LLC significantly increased its stake in Relay Therapeutics (NASDAQ:RLAY) by 591.7%, acquiring an additional 189,004 shares to own a total of 220,949 shares valued at $1.87 million. Other institutional investors have also adjusted their positions in the company, which continues to see strong institutional ownership. Analysts maintain a "Moderate Buy" rating with a consensus target price of $18.00, despite the company remaining unprofitable and recent insider stock sales.
Relay Therapeutics (RLAY) Surges 16.4%: Is This an Indication of Further Gains?
Relay Therapeutics (RLAY) shares surged 16.4% on higher-than-average trading volume, indicating growing investor confidence, particularly due to its lead asset zovegalisib entering late-stage development. The company also has other pipeline advancements and an NDA filed for lirafugratinib. Analysts have revised EPS estimates upward, suggesting potential for further stock price appreciation.
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Relay Therapeutics (NASDAQ:RLAY) has received a "Moderate Buy" consensus rating from analysts, with an average 1-year price target of $18. This comes amidst several firms raising their price targets for the stock, including Guggenheim to $22 and HC Wainwright to $19. Despite insider selling by the CEO and CFO, the company recently reported stronger-than-expected quarterly earnings, beating EPS estimates and exceeding revenue forecasts.
Relay Therapeutics (RLAY) Jumps 16.4%: Does This Signal More Upside Ahead?
Relay Therapeutics (RLAY) saw its shares jump by 16.4% due to optimism surrounding its leading drug candidate, zovegalisib, currently in Phase III trials for breast cancer, and other drugs in its pipeline. The company is expected to report improved quarterly earnings and revenue, with analysts raising EPS estimates, which historically correlates with short-term stock price gains. Investors are advised to monitor the stock's momentum, which currently holds a Zacks Rank #3 (Hold).
Relay Therapeutics (RLAY) climbs 16% ahead of cancer treatment update
Shares of Relay Therapeutics (RLAY) rose 16% in premarket trading. The surge is attributed to investor anticipation of an update on the company's cancer drug development, particularly its RLY-2608 compound for PI3Kα-mutant solid tumors, at an upcoming medical conference.
Relay Therapeutics (NASDAQ:RLAY) Reaches New 52-Week High - Time to Buy?
Relay Therapeutics (NASDAQ:RLAY) shares recently hit a new 52-week high of $13.04, trading on heavy volume after closing at $10.77. Analysts maintain a "Moderate Buy" consensus with an average price target of $18.00, with some increasing their targets up to $19.00. Despite still being unprofitable, the company reported a modest earnings beat, with EPS of ($0.32) and revenue of $7.0 million against estimates.
Relay Therapeutics to Present Initial Clinical Data on Zovegalisib at Vascular Anomalies Conference
Relay Therapeutics will present initial clinical data and preclinical data for its investigational drug zovegalisib (RLY-2608) at the International Society for the Study of Vascular Anomalies (ISSVA) World Congress 2026. Zovegalisib is a mutant-selective PI3Kα inhibitor designed to treat PIK3CA-driven vascular malformations, aiming to address a significant unmet need for an estimated 170,000 patients annually in the United States. The presentation will include data from approximately 20 efficacy-evaluable patients, marking a key milestone in the drug's development.
Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026
Relay Therapeutics announced it will present initial clinical data for zovegalisib (RLY-2608) in vascular anomalies at the International Society for the Study of Vascular Anomalies (ISSVA) World Congress 2026 in May. The presentation will include results from approximately 20 efficacy-evaluable patients. Zovegalisib is a mutant-selective PI3Kα inhibitor, a leading program for treating cancers and genetic diseases.
Relay Therapeutics (RLAY) Climbs 16% Ahead of Cancer Treatment Update
Relay Therapeutics Inc. (NASDAQ:RLAY) saw its stock climb 16.43% as investors anticipated updates on its cancer treatment, Zovegalisib. The company is set to present updated initial clinical trial data for Zovegalisib at the ISSVA World Congress in May 2026. This treatment, designed for HR+, HER2- breast cancer patients with a PI3Kα mutation and those with vascular anomalies, has shown "robust efficacy" at its recommended Phase 3 dose.
5 Stocks With Easy 8-20% Gains
This article identifies five stocks with potential for 8-20% gains, starting with Relay Therapeutics Inc. (NASDAQ:RLAY). Relay Therapeutics recently saw a 16.43% jump after announcing updated data for its cancer treatment, Zovegalisib, to be presented at an upcoming congress in May 2026. The company reported "robust efficacy" for Zovegalisib in combination with fulvestrant for HR+, HER2- breast cancer with a PI3Kα mutation and vascular anomalies.
Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026
Relay Therapeutics announced it will present initial clinical results and preclinical data for zovegalisib (RLY-2608) in vascular anomalies at the ISSVA World Congress 2026. The company expects to report clinical data from approximately 20 efficacy-evaluable patients. Zovegalisib is a novel, mutant-selective PI3Kα inhibitor designed to address limitations of traditional PI3Kα inhibitors and is being evaluated for breast cancer and PI3Kα-driven vascular anomalies.
First zovegalisib results in about 20 vascular anomaly patients due in May
Relay Therapeutics (Nasdaq: RLAY) announced it will present initial clinical data for zovegalisib in approximately 20 vascular anomaly patients at the ISSVA World Congress 2026 in May. The data, expected on May 20, 2026, will detail efficacy in PIK3CA-driven vascular malformations, alongside preclinical results showing lesion regression with minimal hyperinsulinemia. This marks an expansion of zovegalisib's development beyond its existing metastatic breast cancer trials.
Relay Therapeutics stock hits 52-week high at $11.52 By Investing.com
Relay Therapeutics (RLAY) stock reached a new 52-week high of $11.52, reflecting a 388.21% increase over the past year and a 106% gain in the last six months. This surge is attributed to investor confidence in the biotech firm's drug discovery pipeline and positive analyst revisions, particularly concerning its breast cancer drug, zovegalisib. However, InvestingPro analysis suggests the stock might be overvalued at its current levels.
Relay Therapeutics stock hits 52-week high at $11.52
Relay Therapeutics Inc. (RLAY) stock has reached a 52-week high of $11.52, reflecting a 388.21% gain over the past year and a 106% gain in the last six months. This surge is attributed to investor confidence in the biotech firm's innovative drug discovery approach, positive analyst revisions, and promising Phase 1/2 trial data for its breast cancer drug, zovegalisib. However, InvestingPro analysis suggests the stock may currently be overvalued.
Relay Therapeutics stock hits 52-week high at $11.52 By Investing.com
Relay Therapeutics (RLAY) stock reached a new 52-week high of $11.52, reflecting a 388.21% appreciation over the past year and a 106% gain in the last six months. This surge is attributed to investor confidence in its innovative drug discovery, recent positive Phase 1/2 trial data for its breast cancer drug zovegalisib, and subsequent upward revisions of price targets by multiple analysts. Despite concerns about potential overvaluation, the company's strong pipeline and strategic initiatives are driving its robust stock performance.
Assessing Relay Therapeutics (RLAY) Valuation After New ReDiscover Trial Data And FDA Breakthrough Status
Relay Therapeutics (RLAY) is under evaluation after releasing new Phase 1/2 ReDiscover trial data for zovegalisib, supporting its Phase 3 dosing regimen, and receiving FDA Breakthrough Status. Despite recent stock volatility, including a significant 1-year return, the company's Price-to-Book ratio of 3x indicates investors are recognizing growth potential but also acknowledging risks like ongoing net losses. The article suggests investors should conduct their own due diligence to assess the company's future prospects.
Assessing Relay Therapeutics (RLAY) Valuation After New ReDiscover Trial Data And FDA Breakthrough Status
Relay Therapeutics (RLAY) is under valuation assessment following new Phase 1/2 ReDiscover trial data for zovegalisib and fulvestrant, which supports its selected Phase 3 dosing regimen for metastatic breast cancer. Despite recent short-term negative stock performance, the company shows a significant one-year return, though still below its five-year starting point. Trading at a price-to-book ratio of 3x, the market is assigning Relay a higher valuation than the typical biotech, yet at a discount to peers, indicating investor recognition of future growth potential despite ongoing losses and trial risks.
Relay Therapeutics (RLAY) price target increased by 17.50% to 17.43
The price target for Relay Therapeutics (RLAY) has been increased by 17.50% to $17.43. This update reflects a significant change in the financial outlook or analyst's valuation of the company's stock. Investors may consider this information as part of their assessment of RLAY's potential.
Vanguard realignment reports 0 Relay Therapeutics shares (RLAY)
The Vanguard Group has filed an amendment to its Schedule 13G/A, reporting zero beneficial ownership in Relay Therapeutics Inc Common Stock (RLAY). This change follows an internal realignment effective January 12, 2026, where subsidiaries disaggregated their holdings and now report separately. The filing clarifies that Vanguard no longer has beneficial ownership of these securities.
RLAY SEC Filings - Relay Therapeutics, Inc. 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides a comprehensive resource for investors to access Relay Therapeutics, Inc. (RLAY) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading reports. It highlights how these documents offer insights into the company's financial condition, governance, and material developments related to its clinical-stage programs like RLY-2608. The platform also offers AI-powered summaries to help users quickly understand key points from these regulatory disclosures.
PERCEPTIVE ADVISORS LLC Acquires Significant Stake in Relay Ther
PERCEPTIVE ADVISORS LLC has acquired 7,501,480 additional shares of Relay Therapeutics Inc (RLAY) at $10.55 per share, increasing its total holdings to 9,404,725 shares. This move signifies the firm's continued confidence in the biotechnology sector and Relay Therapeutics' innovative approach to drug discovery, despite the company's current overvaluation and challenges in profitability. Relay Therapeutics, a clinical-stage precision medicine company, leverages its Dynamo platform for drug-protein targeting in oncology and genetic diseases.
Relay Therapeutics unveils educational resource on mutant selective PI3Kα inhibitor for vascular anomalies
Relay Therapeutics has launched a webinar to educate healthcare professionals and stakeholders on vascular anomalies and the therapeutic options available, including its mutant-selective PI3Kα inhibitor, zovegalisib. The initiative aims to enhance understanding of disease mechanisms and targeted therapies. This follows the company's advancement of zovegalisib into Phase 3 trials in combination with fulvestrant, based on promising Phase 1/2 data.
HC Wainwright Has Positive Outlook for RLAY Q1 Earnings
HC Wainwright has increased its Q1 2026 EPS estimate for Relay Therapeutics (NASDAQ: RLAY) from ($0.43) to ($0.36) per share, maintaining a "Buy" rating and a $19 price target. This positive outlook follows Relay's recent earnings beat, where the company reported ($0.32) EPS against an estimated ($0.38) and $7.0M in revenue versus $4.34M expected. The stock currently trades around $9.44, with a consensus analyst target of $18, indicating a "Moderate Buy" rating.
Did Phase 1/2 ReDiscover Data Just Reframe Relay Therapeutics' (RLAY) Late-Stage Breast Cancer Strategy?
Relay Therapeutics (RLAY) recently released updated Phase 1/2 ReDiscover trial data for zovegalisib, confirming the 400mg twice-daily fed dose for PI3Ka-mutated, HR+/HER2- metastatic breast cancer due to its efficacy and tolerability. This data de-risks the ongoing Phase 3 trial and supports the direct comparison of zovegalisib plus fulvestrant against capivasertib plus fulvestrant, reinforcing the company's investment narrative focused on its drug discovery engine and late-stage assets. However, the company remains dependent on zovegalisib's Phase 3 outcome, and current valuations suggest it may be overvalued.
Did Phase 1/2 ReDiscover Data Just Reframe Relay Therapeutics' (RLAY) Late-Stage Breast Cancer Strategy?
Relay Therapeutics announced updated Phase 1/2 ReDiscover trial data for its drug zovegalisib, showing efficacy and tolerability at a 400mg fed dose consistent with an earlier 600mg fasted regimen in metastatic breast cancer. This data confirms the recommended Phase 3 dose, supports the ongoing Phase 3 ReDiscover-2 trial, and reinforces the clinical strategy for the FDA Breakthrough Therapy-designated drug. The announcement is a de-risking factor for the company's investment narrative, particularly concerning the upcoming Phase 3 trial.
Did Phase 1/2 ReDiscover Data Just Reframe Relay Therapeutics' (RLAY) Late-Stage Breast Cancer Strategy?
Relay Therapeutics reported updated Phase 1/2 ReDiscover trial data showing its drug zovegalisib, combined with fulvestrant, is effective and tolerable at a 400mg twice-daily fed dose in PI3Ka-mutated, HR+/HER2- metastatic breast cancer patients, consistent with earlier results. This dosage has been confirmed for the ongoing global Phase 3 ReDiscover-2 trial, reinforcing the clinical rationale and the drug's FDA Breakthrough Therapy designation. The data helps de-risk the Phase 3 trial, which is a key short-term catalyst for Relay Therapeutics, although the company's valuation remains a point of discussion among investors.
RLAY: HC Wainwright & Co. Raises Price Target to $19.00, Maintai
HC Wainwright & Co. has increased its price target for Relay Therapeutics (RLAY) to $19.00 from $14.00, while maintaining a "Buy" rating, reflecting strong analyst confidence. This follows various other analysts, including Wells Fargo, Citizens, and Guggenheim, who have also raised their price targets for RLAY in recent weeks. Despite a strong "Buy" consensus from brokerage firms, GuruFocus estimates a potential downside based on its GF Value of $2.70 compared to the current price of $9.89.
H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $19
H.C. Wainwright has reiterated its Buy rating for Relay Therapeutics (RLAY.US) and increased the target price to $19.
Assessing Relay Therapeutics (RLAY) Valuation After New Zovegalisib Breast Cancer Data And Ongoing Phase 3 Trial
Relay Therapeutics (RLAY) is being re-evaluated after presenting new Phase 1/2 ReDiscover data for zovegalisib in breast cancer, showing efficacy and safety. Despite a significant 223.86% shareholder return over the past year, the company's valuation is complex, with a Price-to-Book ratio of 3.1x appearing expensive against the broader US biotech industry but inexpensive compared to its peer group. The article highlights the mixed sentiment due to clinical and regulatory uncertainties, ongoing losses, and the potential for both rewards and risks.
Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026
Relay Therapeutics announced positive data from its Phase 1/2 ReDiscover trial for zovegalisib plus fulvestrant, presented at the ESMO Targeted Anticancer Therapies Congress 2026. The 400mg BID fed regimen, matching the Phase 3 dose, demonstrated robust efficacy with a median progression-free survival of 11.1 months in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer, alongside a consistent and favorable safety profile. These results support the ongoing Phase 3 ReDiscover-2 trial, for which zovegalisib has received FDA Breakthrough Therapy designation.
Assessing Relay Therapeutics (RLAY) Valuation After New Zovegalisib Breast Cancer Data And Ongoing Phase 3 Trial
Relay Therapeutics (RLAY) is gaining investor attention following new Phase 1/2 ReDiscover data for its breast cancer drug zovegalisib, showing efficacy and safety. The stock has seen significant momentum, with a 223.86% return over the past year, and it trades at a Price-to-Book ratio of 3.1x, which is considered about right when weighed against industry peers and the company's clinical stage. Despite mixed sentiment due to clinical uncertainties and ongoing losses, the new data provides a catalyst for re-evaluation.
Raymond James reiterates Strong Buy on Relay Therapeutics stock
Raymond James has reiterated a Strong Buy rating and a $19.00 price target for Relay Therapeutics (NASDAQ:RLAY) after Novartis announced its acquisition of a competing drug candidate. The firm believes that Relay's current enterprise value is undervalued, especially considering recent pharmaceutical mergers and acquisitions. Relay Therapeutics is actively testing its drug zovegalisib, with promising Phase 1/2 trial data released and the drug receiving Breakthrough Therapy designation from the FDA, leading to positive analyst perspectives.
Relay Therapeutics Price Target Raised to $17.00
Wells Fargo & Company has increased its price target for Relay Therapeutics (NASDAQ:RLAY) from $15.00 to $17.00, maintaining an "overweight" rating. This adjustment reflects optimism regarding the clinical-stage biotech company's oncology drug development pipeline, despite mixed ratings from other analysts. The average target price for Relay Therapeutics now stands at $17.17.
Relay Therapeutics (RLAY) — Perceptive entities report 5.3% stake
Perceptive Life Sciences Master Fund, Perceptive Advisors LLC, and Joseph Edelman have disclosed a 5.3% beneficial ownership stake in Relay Therapeutics (RLAY), totaling 9,404,725 shares of Common Stock. This ownership represents shared voting and dispositive power among the entities. The percentage calculation is based on 178,725,809 shares outstanding as of February 20, 2026, as reported in Relay Therapeutics' Form 10-K.
Nextech Invest Increases Relay Therapeutics Stake in Q4 2025 | Portfolio Update - News and Statistics
Nextech Invest, Ltd. significantly increased its stake in Relay Therapeutics during Q4 2025 by acquiring over 855,000 additional shares, valued at approximately $6.1 million. This transaction, combined with market price movements, raised Nextech's total position in Relay Therapeutics by $19.7 million, making it 3.9% of the firm's reportable assets. Relay Therapeutics, a clinical-stage biotechnology company, is developing precision medicines in oncology and genetic diseases and had a market capitalization of $1.77 billion as of March 17, 2026.
Is Relay Therapeutics Worth Buying in 2026? A Major Institutional Investor Has Just Placed a $6 Million Wager.
Nextech Invest, a major institutional investor, recently acquired an additional $6.1 million worth of Relay Therapeutics (NASDAQ:RLAY) shares, significantly increasing its position in the company. Relay Therapeutics specializes in precision medicine for cancer and genetic disorders and has seen its share price nearly triple over the past year. While Nextech's investment is noteworthy, the article advises retail investors to consider Relay's progress and potential risks, suggesting oncology-focused biotech ETFs for broader exposure.
Wells Fargo & Company Boosts Relay Therapeutics (NASDAQ:RLAY) Price Target to $17.00
Wells Fargo & Company has increased its price target for Relay Therapeutics (NASDAQ:RLAY) to $17.00, maintaining an "overweight" rating and suggesting a potential upside of 71.2%. This rating contributes to a "Moderate Buy" consensus among analysts with an average target price of $17.20, though some analysts like Guggenheim are more bullish, setting a $22 target. The company recently surpassed quarterly earnings and revenue estimates, and, despite some insider selling, institutional investors have increased their holdings.
Relay Therapeutics (RLAY) Sees Price Target Raised by Wells Farg
Wells Fargo has increased its price target for Relay Therapeutics (RLAY) from $15.00 to $17.00, while maintaining an "Overweight" rating, signaling confidence in the company's potential. This adjustment follows several other recent upgrades and price target increases from various analysts. Despite positive analyst sentiment and an average target price suggesting a significant upside, GuruFocus' estimated fair value (GF Value) indicates a potential downside for RLAY.
Relay Therapeutics (RLAY) shows 11.1-month PFS with zovegalisib combo in PI3Kα-mutated breast cancer
Relay Therapeutics announced new Phase 1/2 data for its PI3Kα inhibitor zovegalisib combined with fulvestrant in PI3Kα-mutated, HR+/HER2- metastatic breast cancer, showing a median progression-free survival of 11.1 months at the recommended 400mg BID fed dose. The regimen demonstrated encouraging efficacy and a manageable safety profile, supporting its use in the ongoing global Phase 3 ReDiscover-2 trial, which has FDA Breakthrough Therapy designation. This data indicates zovegalisib's potential as a differentiated approach for heavily pre-treated patients.
Relay Therapeutics reports 11.1-month median PFS for zovegalisib 400mg BID fed in PI3Kα-mutant MBC
Relay Therapeutics announced an 11.1-month median progression-free survival (PFS) for its drug zovegalisib (400mg BID fed plus fulvestrant) in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer. The Phase 1/2 ReDiscover study, involving 60 patients, showed a confirmed overall response rate of 43% and was generally well-tolerated with comparable pharmacokinetic exposures to a higher fasted dose. This data was reported based on an SEC filing.
Relay Therapeutics Sees Unusually Large Options Volume
Shares of Relay Therapeutics (NASDAQ: RLAY) experienced unusually high options trading volume on Monday, with investors purchasing 5,148 call options, a 1,428% increase from the average. This surge in activity suggests investors may be speculating on the clinical-stage biotech company's future performance, despite its shares trading down 0.4% on the day. The company, focused on oncology therapies, has a market capitalization of $1.84 billion and recently exceeded analyst earnings estimates despite posting a loss.
Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026
Relay Therapeutics (Nasdaq: RLAY) announced positive data from its Phase 1/2 ReDiscover trial for zovegalisib in combination with fulvestrant, presented at the ESMO Targeted Anticancer Therapies Congress 2026. The data, using the 400mg BID fed dose (the recommended Phase 3 dose), showed a median progression-free survival of 11.1 months in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer. This regimen exhibited robust efficacy and a favorable safety profile, consistent with previous findings, bolstering confidence in its advancement into the ongoing Phase 3 ReDiscover-2 trial.
Relay Therapeutics Highlights Positive Zovegalisib ReDiscover Trial Data
Relay Therapeutics announced positive Phase 1/2 ReDiscover trial data for its PI3Kα inhibitor zovegalisib combined with fulvestrant in metastatic breast cancer patients. The 400mg BID fed regimen achieved an 11.1-month median progression-free survival and was well-tolerated, demonstrating comparable exposure to the previous 600mg fasted dose. These results support its use in the ongoing Phase 3 ReDiscover-2 trial and strengthen Relay's position in targeted breast cancer therapies.
Experimental Relay cancer drug combo shows 11.1-month progression-free survival
Relay Therapeutics announced positive Phase 1/2 ReDiscover data for zovegalisib plus fulvestrant in PI3Kα‑mutated, HR+/HER2‑ metastatic breast cancer, showing a median progression-free survival of 11.1 months. The 400mg BID fed regimen demonstrated comparable pharmacokinetics to the 600mg fasted dose with a manageable safety profile, supporting its advancement into the ongoing Phase 3 ReDiscover-2 trial. Zovegalisib has also received FDA Breakthrough Therapy designation for this patient population.
Commodore Capital Boosts Stake in Relay Therapeutics
Commodore Capital LP has significantly increased its stake in Relay Therapeutics (NASDAQ:RLAY) by 27.3% in the third quarter of 2026, making it the biotech company's largest institutional investor with 17 million shares. This move suggests the hedge fund's confidence in Relay Therapeutics' drug development pipeline and future growth prospects. As a major shareholder, Commodore Capital's increased investment could influence the strategic direction of Relay Therapeutics.
Should Relay’s Zovegalisib Momentum and New Legal Forum Rules Require Action From Relay Therapeutics (RLAY) Investors?
Relay Therapeutics recently amended its bylaws to make U.S. federal district courts the exclusive forum for securities law claims, while its CFO sold shares. Despite this, investor focus remains on the positive momentum of Relay's zovegalisib phase III program for breast cancer and increased consensus EPS estimates. The article suggests investors should consider the implications of these developments, including a potential overvaluation and insider selling, alongside the promising drug trial results.
Guggenheim Raises Price Target for Relay Therapeutics (RLAY) to $22 | RLAY Stock News
Guggenheim has raised its price target for Relay Therapeutics (RLAY) to $22 from $15, maintaining a "Buy" rating. This optimistic adjustment reflects a 46.67% increase in the target. Other analysts have also adjusted their ratings and price targets for RLAY, with the average analyst target price suggesting a 48.21% upside from the current price.
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of "Moderate Buy" from Analysts
Relay Therapeutics (NASDAQ:RLAY) has earned a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $15.40. The company recently surpassed quarterly earnings estimates, reporting ($0.32) EPS against a ($0.38) consensus and $7.0 million in revenue compared to an expected $4.34 million. Despite recent insider selling, institutional ownership remains high at nearly 97%.
